NCT06551233View on ClinicalTrials.gov

Safety and Efficacy of 9MW2821 in the Treatment of High-risk Non-muscle-invasive Bladder Cancer (NMIBC)

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 22, 2024

Primary Completion Date

November 30, 2024

Study Completion Date

December 31, 2025

Conditions
Bladder Cancer
Interventions
DRUG

9MW2821

Patients will be evaluated from low dose to high dose through intravesical therapy and then select the suitable doses to expand according to study data.

Trial Locations (1)

Unknown

RECRUITING

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing

All Listed Sponsors
lead

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

OTHER